The main protease (Mpro) of SARS-CoV-2 is an attractive drug target for antivirals, as this enzyme plays a key role in virus replication. Drug repurposing is a promising option for the treatment of coronavirus disease 2019 (COVID-19). Recently, a number of FDA-approved drugs have been identified as Mpro inhibitors, but stringent hit validation is lacking. In this study, we rigorously reevaluated the in vitro inhibition of the Mpro enzyme by repurposed drugs via combined experiments, including the fluorescence resonance energy transfer (FRET) assay, fluorescence polarization (FP) assay, and protease biosensor cleavage assay. Our results from a set of in vitro assays revealed that boceprevir is a potential Mpro inhibitor, but other repurposed drugs, including atazanavir, dipyridamole, entrectinib, ethacridine, glecaprevir, hydroxychloroquine, ivermectin, meisoindigo, pelitinib, raloxifene, roxatidine acetate, saquinavir, teicoplanin, thonzonium bromide, and valacyclovir, are not. Our research highlights that the use of candidate Mpro inhibitors from primary screening warrants further comprehensive studies before the reporting of new findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmv.70229 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of COVID-19 on tuberculosis and HIV health services delivery in Ghana: qualitative evidence from the perspectives of healthcare providers.
BMC Health Serv Res
March 2025
Asian Institute for Bioethics and Health Law, College of Medicine, Yonsei University, Seoul, Korea.
Introduction: The COVID-19 burden, coupled with unprecedented control measures including physical distancing, travel bans, and lockdowns in cities, has undoubtedly far-reaching consequences on healthcare services and has affected human immunodeficiency virus (HIV) and tuberculosis (TB) health services in both low- and high-income countries. This study, therefore, explored the perspective of HIV and TB health service providers to better understand how the pandemic impacted health service delivery in Ghana.
Method: This qualitative explorative study was conducted among HIV and TB healthcare providers (n = 30) in six districts of Ghana from March to May 2021 using in-depth interviews.
Metal-Based Approaches for the Fight against Antimicrobial Resistance: Mechanisms, Opportunities, and Challenges.
J Am Chem Soc
March 2025
Department of Chemistry, The University of Hong Kong, Pokfulam Road, Hong Kong SAR, PR China.
The rapid emergency and spread of antimicrobial-resistant (AMR) bacteria and the lack of new antibiotics being developed pose serious threats to the global healthcare system. Therefore, the development of more effective therapies to overcome AMR is highly desirable. Metal ions have a long history of serving as antimicrobial agents, and metal-based compounds are now attracting more interest from scientific communities in the fight against AMR owing to their unique mechanism.
View Article and Find Full Text PDFNovel effects of reverse transcriptase inhibitor supplementation in skeletal muscle of old mice.
Physiol Genomics
March 2025
Department of Health & Exercise Science, Colorado State University, Fort Collins, CO.
Aging is the primary risk factor for the development of many chronic diseases, including dementia, cardiovascular disease, and diabetes. There is significant interest in identifying novel "geroprotective" agents, including by repurposing existing drugs, but such treatments may affect organ systems differently. One current example is the nucleoside reverse transcriptase inhibitor 3TC, which has been increasingly studied as a potential gerotherapeutic.
View Article and Find Full Text PDFDespite numerous research efforts and several effective vaccines and therapies developed against COronaVIrus Disease 2019 (COVID-19), drug repurposing remains an attractive alternative to identify new treatments for SARS-CoV-2 virus variants and other viral infections that may emerge in the future. Cellular polyamines support viral propagation and tumor growth. Here we tested the antiviral activity of an irreversible inhibitor of polyamine biosynthesis, α-difluoromethylornithine (DFMO) and a non-steroidal anti-inflammatory drug (NSAID) Sulindac, which have been previously evaluated for colon cancer chemoprevention.
View Article and Find Full Text PDFRepurposing Secukinumab and Dapagliflozin as Candidate Therapies to Mitigate the Renal Toxicity of Sunitinib in Rats Through Suppressing IL-17-Mediated Pyroptosis and Promoting Autophagy.
J Biochem Mol Toxicol
March 2025
Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Sunitinib (SUN) is a chemotherapeutic agent showing renal toxicity that limits its clinical applications. The present research aimed to clarify the potential ameliorative effects of secukinumab (SEC) and dapagliflozin (DAPA) against SUN-induced renal toxicity and the underpinning molecular mechanisms. For this purpose, adult Wistar albino rats were received SUN (25 mg/kg 3 times/week, po) and co-treated with SEC (3 mg/kg/every 2 weeks, subcutaneously) or DAPA (10 mg/kg/day, po) for 4 weeks and compared with age-matched control group (CON).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!